Video Series

Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.

A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.

Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.

A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.

A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.

Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.

Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.

An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.

Dr Yi-Bin Chen shares his thoughts on future directions and unmet needs in treatment of steroid-refractory GVHD.

Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.

Dr Yi-Bin Chen reviews treatment options for patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, discusses several approaches to the treatment of steroid-refractory acute GVHD, along with the immunologic pathways they target.

An expert in bone marrow transplantation outlines the main therapy used in the front-line setting to treat GVHD and then provides several definitions of what it means to be steroid-refractory.

Dr Yi-Bin Chen describes several prophylactic regimens commonly used to prevent GVHD following allogeneic hematopoietic stem cell transplant.

Yi-Bin Chen, MD, delineates between acute and chronic GVHD and provides the incidence and risk factors associated with these diseases.

Richard S. Finn, MD concludes the discussion by commenting on areas of unmet need in the care of HCC and emphasizes the potential impact of trials studying treatment combination and sequencing.

A thought leader in the management of hepatocellular carcinoma provides an overview of several clinical trials of combination therapy with lenvatinib including studies of real-world evidence and potential biomarkers.

An expert hematologist-oncologist considers the potential role of combination therapy with lenvatinib for patients with hepatocellular carcinoma.

A key opinion leader in liver cancer reviews the study design of the REFLECT trial of lenvatinib in patients with HCC and shares key insights into its safety and efficacy data.

Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.

An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.

Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.

Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).

Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.

A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.